These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 24080741)

  • 1. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.
    Eschbach J; Danzer KM
    Neurodegener Dis; 2014; 14(1):1-17. PubMed ID: 24080741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
    Sato H; Kato T; Arawaka S
    Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-synuclein-based models of Parkinson's disease.
    Dehay B; Fernagut PO
    Rev Neurol (Paris); 2016; 172(6-7):371-8. PubMed ID: 27158042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
    Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
    Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Drosophila model of Parkinson's disease.
    Feany MB; Bender WW
    Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral vectors, animal models and new therapies for Parkinson's disease.
    Schneider B; Zufferey R; Aebischer P
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S169-71. PubMed ID: 18585946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Parkinson's disease pathology be propagated from one neuron to another?
    Dunning CJ; Reyes JF; Steiner JA; Brundin P
    Prog Neurobiol; 2012 May; 97(2):205-19. PubMed ID: 22115849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
    Caudal D; Alvarsson A; Björklund A; Svenningsson P
    Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of alpha-synuclein in Parkinson's disease].
    Miklya I; Pencz N; Hafenscher F; Göltl P
    Neuropsychopharmacol Hung; 2014 Jun; 16(2):77-84. PubMed ID: 24978050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.